Two different lenses on the same repair

Coming across 'IKDC' or 'MOCART' in a clinic letter or follow-up report can feel like reading a different language — yet both terms describe something quite straightforward. The IKDC score captures how you feel: how much pain, stiffness, or limitation you notice day to day. The MOCART score captures what the repair tissue actually looks like on an MRI scan.

Each measure fills a gap the other cannot. The IKDC is a questionnaire of 18 items spread across symptoms, sport participation, and daily activities, scored from 0 to 100 — where 100 represents the highest possible level of knee function. It is entirely patient-reported; no imaging needed. MOCART 2.0, introduced by Schreiner and colleagues in 2019, takes the opposite vantage point: a radiologist assesses seven structural variables on MRI, starting with how fully the defect has filled and how well the new tissue integrates with the surrounding cartilage.

The two scores do not always move in step — a scan can look encouraging before a patient feels fully recovered, or vice versa — which is precisely why both are used together as tracking tools rather than as a single pass-or-fail verdict.

The 30-point IKDC gain and what it means in practice

An IKDC score of around 80 translates, in practical terms, to being able to walk without significant pain, manage stairs, return to low-to-moderate recreational activity, and carry out most daily tasks without the knee imposing an obvious ceiling. That is where patients in the Jerosch prospective cohort — the largest ChondroFiller knee study in the published record, and one drawn from manufacturer-sponsored investigations rather than independent randomised trials — arrived at one year, and where most remained at three-year follow-up.

Reaching that point typically involved a gain of approximately 30 IKDC points over the first 12 months. To put that in context: the established minimum clinically important difference (MCID) for IKDC is 16.7 points — the boundary below which a change is unlikely to feel meaningful to the patient. A 30-point improvement roughly doubles that threshold, moving patients well into territory where the difference is felt in daily life, not just detectable on a scoring sheet.

Across four ChondroFiller knee studies, that circa-30-point gain was consistent. In the Jerosch cohort it measured 32.4 points and was sustained — and slightly increased — at the three-year mark, suggesting the repair tissue matures rather than deteriorating once the scaffold has been fully replaced by the patient's own cells. The figures relate to the ultrasound-guided injectable collagen scaffold pathway delivered as an outpatient procedure; independent randomised comparison data remain limited, so they should be interpreted in that light.

What MOCART scores reveal — and why timing matters

The scaffold's biological behaviour explains why MOCART scores taken early in recovery look markedly different from those at 12 months — and why that difference is expected rather than alarming.

Once the injectable collagen scaffold gels in situ within a few minutes of placement, the repair process driven by acellular matrix-induced chondrogenesis begins: the patient's own progenitor cells, drawn from the surrounding synovium and subchondral bone, migrate into the scaffold over the following days to weeks and gradually differentiate into cartilage-forming cells. Active new tissue deposition continues across the first 12 months, and the scaffold is progressively replaced by the patient's own repair tissue, with full resorption typically complete between one and two years post-procedure.

That biological arc maps directly onto the MOCART trajectory seen in European studies. Mean scores in ChondroFiller knee patients measured approximately 65 at four weeks — reflecting early, still-maturing repair tissue — and rose to between 81 and 84 at 12 months. A result in that 81–84 range at one year indicates the treated defect has achieved greater than 80% volumetric fill, meaning the joint surface has largely regained its structural depth.

The practical implication for anyone whose three-month scan returns a lower number: the repair tissue is still being laid down at that stage, and a score in the mid-60s is consistent with normal biological progress, not a sign the approach has failed. The 12-month scan is a more informative structural benchmark, and tissue remodelling may continue to refine the result through the second year.

Normal early MRI appearances versus findings that need review

Most scan reports following cartilage repair contain findings that, read in isolation, sound more serious than they are. Bone marrow oedema — a bright signal in the bone directly beneath the treated site — appears in the majority of patients after cartilage repair and is a normal part of the healing response for up to 18 months. Radiologists note it because it is present; that notation alone does not indicate failure or inadequate integration.

The timing of these findings matters considerably. Oedema that persists beyond 18 months warrants a conversation with the treating specialist, as a prolonged signal may reflect suboptimal tissue integration rather than ongoing normal healing. A similar interpretive pattern applies to the cartilage–repair interface: streaky or bright signal at the border between repair tissue and surrounding native cartilage is common in early post-procedure scans and represents an expected transitional stage. When that same interface signal remains clearly visible at 12–18 months or beyond, it becomes a more meaningful structural finding worth raising at follow-up.

Defect fill volume — the leading variable in MOCART assessment — follows its own predictable course: partial fill at early scans is expected; incomplete fill at 12 months carries considerably more interpretive weight as a structural signal, for reasons covered in the previous section.

Patients receiving a scan report will not see a MOCART score presented as a single number to interpret independently. The assessment is produced by a musculoskeletal radiologist and contextualised by the treating team. Knowing these terms serves one practical purpose: it equips patients — and the GPs or physiotherapists supporting them — to ask more precise questions at follow-up rather than draw premature conclusions from the written report alone.

How these scores sit alongside other cartilage repair options

Placing ChondroFiller outcomes in a wider context means comparing techniques with different risk profiles — not ranking them as better or worse overall.

The approximately 30-point IKDC gain reported across ChondroFiller knee studies sits within the range published for autologous chondrocyte implantation (ACI) and its matrix-associated variant MACI, where improvements of roughly 30 to 35 points have been documented. The substantive difference lies in the pathway: ACI and MACI are staged surgical procedures, whereas ChondroFiller is delivered as a single-stage injectable treatment in an outpatient setting.

Microfracture occupies a different position in the comparison. It stimulates fibrocartilage rather than hyaline-like repair tissue — a structural distinction reflected in MOCART assessments — and published series have cited reoperation rates of up to 41%. ACI and MACI produce more durable repair tissue but carry reported complication rates of up to 17% and reoperation rates of up to 37%. In available ChondroFiller studies, the reported complication rate is approximately zero, with reoperation at 3–8%.

Those comparisons come with an important qualification: no independent, head-to-head randomised controlled trial comparing ChondroFiller with ACI or MACI has been published in the peer-reviewed literature. The clinical evidence on ChondroFiller comes from manufacturer-sponsored evaluations, and long-term MOCART data beyond three years are not yet available. Both are genuine gaps in the current evidence picture, and worth raising in any specialist consultation when weighing treatment pathways.

Finding a specialist who tracks your outcomes after the injection

Outcome monitoring — a baseline IKDC questionnaire before treatment, a repeat at 6–12 months, and an MRI reviewed against MOCART criteria at one year — is not an optional extra in a well-structured injectable collagen scaffold pathway. It is how progress is measured rather than assumed.

When assessing a specialist, two practical questions are worth raising: do they record a baseline IKDC score before the injection so improvement can be quantified against a fixed starting point? And what is their follow-up imaging protocol at 12 months? A clear answer to both suggests a pathway built around objective evidence of repair rather than a single-episode intervention with no structured review.

Search MSK lists specialists across the UK who offer ChondroFiller and related cartilage injection therapies — filter by region and specialty to find one suited to your situation. Knowing which questions to ask before you attend that first appointment means you arrive ready to evaluate the pathway, not just accept it.